Amyloidosis is not a cancer. It is a group of diseases caused by misfolded proteins that accumulate as insoluble fibrils in organs and tissues, gradually disrupting their function. The confusion with cancer comes mainly from one specific type, AL amyloidosis, which arises from the same kind of abnormal plasma cells involved in multiple myeloma and is often treated with chemotherapy drugs. But the damage in amyloidosis is not caused by tumor growth or cells dividing out of control. It is caused by rogue proteins physically depositing where they do not belong.
Why Amyloidosis Gets Confused with Cancer
The root of the mix-up is AL (light chain) amyloidosis, the most commonly diagnosed systemic type. In AL amyloidosis, a small clone of plasma cells in the bone marrow produces abnormal immunoglobulin light chains that misfold and deposit as amyloid fibrils throughout the body.1PubMed Central. Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach Plasma cells are the same cell type that goes haywire in multiple myeloma, a blood cancer. AL amyloidosis patients are treated by hematologist-oncologists, often in cancer centers, with drugs originally developed for myeloma. Understandably, many patients hear “chemotherapy” and “bone marrow transplant” and assume they have cancer.
But the mechanism of harm is fundamentally different. In myeloma, the danger comes from the plasma cells themselves: they crowd out healthy bone marrow cells, erode bone, and can form tumors. In AL amyloidosis, the plasma cell population is usually small. The danger comes from what those cells produce: misfolded light-chain proteins that travel through the bloodstream and settle into the heart, kidneys, nerves, and other organs as stiff, insoluble fibrils.2Europe PMC. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication It is the protein deposits, not the cells, that cause organ failure.
That said, the two diseases are not entirely separate. In one study of AL amyloidosis patients, roughly one in five also met diagnostic criteria for multiple myeloma.3PubMed Central. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor The overlap matters clinically because treatment intensity needs to be calibrated carefully. AL amyloidosis patients, whose organs are already stressed by amyloid deposits, tend to tolerate aggressive chemotherapy regimens less well than myeloma patients with similar bone marrow involvement. Experts have emphasized that treating the two diseases with identical drug schedules is one of the most serious errors a clinician can make.4Hemato. Differences and Similarities in Treatment Paradigms and Goals between AL Amyloidosis and Multiple Myeloma
How Amyloid Fibrils Damage Organs
Under certain conditions, normally soluble proteins can convert into highly ordered fibrillar structures that resist the body’s usual protein-recycling machinery.5PubMed. Protein misfolding, functional amyloid, and human disease These fibrils share a characteristic shape: stacked sheets arranged in rigid, non-branching strands that the body cannot break down. Over time they accumulate in the spaces between cells, physically crowding out normal tissue architecture.
The damage is not just mechanical. Studies of nerve and heart tissue from amyloidosis patients show that cells near amyloid deposits shrink and waste away. The fibrils appear to disrupt the membranes of neighboring cells, and earlier, smaller protein clumps called oligomers may be directly toxic on their own.6PubMed Central. The Ultrastructure of Tissue Damage by Amyloid Fibrils The combined effect is a slow, progressive loss of organ function that, left unchecked, leads to organ failure.
The Major Types of Amyloidosis
More than 30 different proteins can misfold and form amyloid in humans, but in clinical practice, three types account for the vast majority of cases. A large analysis of over 16,000 amyloidosis specimens classified by mass spectrometry found that AL made up about 59%, ATTR about 28%, and AA about 3% of cases.7Mayo Clinic Proceedings. Typing of 16,175 Amyloidosis Specimens by Mass Spectrometry-Based Proteomics in a Clinical Laboratory The remaining roughly 10% comprised 18 rarer types.
AL (Light Chain) Amyloidosis
As described above, AL amyloidosis stems from a plasma cell clone producing misfolded light chains. It is the type most often confused with cancer because of its bone-marrow origin and its treatment with anti-cancer drugs. AL amyloidosis can affect virtually any organ, with the heart, kidneys, liver, and nervous system being the most common targets.2Europe PMC. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication Cardiac involvement in particular drives prognosis: how well or poorly the heart is functioning at the time of diagnosis is the strongest predictor of survival.
ATTR (Transthyretin) Amyloidosis
ATTR amyloidosis involves the protein transthyretin, which normally carries thyroid hormone and vitamin A in the blood. It comes in two forms. The hereditary form (ATTRv) results from mutations in the transthyretin gene, with over a thousand different mutations identified globally. One of the most common, p.Val142Ile (formerly called V122I), is carried by roughly 3–4% of Black Americans and predisposes to heart disease later in life. The wild-type form (ATTRwt) involves normal, unmutated transthyretin that becomes unstable with aging, predominantly causing cardiac amyloidosis in older men.
ATTR amyloidosis has nothing whatsoever to do with cancer. There is no abnormal clone, no malignant cell. It is a protein-stability problem. The hereditary form tends to cause more severe nerve damage than the wild-type form, with patients showing greater disability across clinical measures, while the wild-type form is dominated by heart involvement.8PubMed Central. The phenotypic landscape of p.Ala117Ser transthyretin amyloidosis: distinct clinical profiles and outcomes versus wild-type ATTR Both forms are increasingly recognized as more common than previously thought, thanks largely to improved cardiac imaging and broader clinical awareness.
AA (Reactive) Amyloidosis
AA amyloidosis is driven by chronic inflammation. Conditions like rheumatoid arthritis, inflammatory bowel disease, and certain inherited autoinflammatory syndromes cause the liver to produce high levels of serum amyloid A (SAA), an inflammatory protein. When SAA levels stay elevated for years, fragments of the protein can misfold and deposit as amyloid, primarily in the kidneys.9PubMed Central. Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage This type, too, has nothing to do with cancer. The treatment strategy focuses on controlling the underlying inflammatory disease to reduce SAA levels, sometimes using biologic drugs like anti-TNF agents.10PubMed. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis
Localized Amyloidosis
Not all amyloidosis is systemic. In localized amyloidosis, amyloid forms and deposits in only one organ, without spreading elsewhere. Common sites include the bladder, airways, and skin. Localized amyloidosis is considered a benign condition; patients do not develop the cardiac, kidney, or nerve involvement seen in systemic disease.11PubMed Central. The Story of Localized Amyloidosis: Something Old and Something New – A Case Series Treatment is typically surgical removal of the affected tissue rather than chemotherapy. Interestingly, the localized AL form differs from its systemic counterpart at a molecular level: it uses kappa and lambda light chains in roughly equal proportions, whereas systemic AL is overwhelmingly lambda-type.12PubMed Central. Localized AL amyloidosis: a suicidal neoplasm?
Symptoms and How They Vary by Organ
Amyloidosis is notoriously hard to recognize because its symptoms mimic common conditions. The specific symptoms depend entirely on where amyloid deposits accumulate, and since deposits can affect multiple organs simultaneously, the clinical picture is often confusing.
When amyloid targets the heart, it stiffens the heart muscle, leading to a restrictive cardiomyopathy: the heart cannot relax and fill properly between beats. This shows up as shortness of breath, swelling in the legs, fatigue, and exercise intolerance.13PubMed. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association Cardiac amyloidosis can also cause irregular heart rhythms. In the kidneys, the hallmark is protein spilling into the urine, often in large amounts, progressing toward kidney failure.14The American Journal of Medicine. Renal Amyloidosis: Presentation, Diagnosis, and Management Renal amyloidosis is most commonly seen in the AL and AA types.
Nerve involvement produces numbness, tingling, and pain, usually starting in the feet and hands and working upward. Amyloid can also damage the autonomic nerves that control blood pressure, digestion, and bladder function, leading to symptoms like dizziness on standing, chronic diarrhea or constipation, and erectile dysfunction.15PubMed Central. Amyloid neuropathies Other symptoms that may raise suspicion include an enlarged tongue (almost unique to AL amyloidosis), easy bruising around the eyes (“raccoon eyes”), and carpal tunnel syndrome in both wrists, which is a surprisingly common early sign of ATTR amyloidosis.
The Diagnosis Challenge
Diagnosing amyloidosis is difficult for two reasons: the symptoms overlap heavily with far more common diseases, and confirming the diagnosis requires tissue evidence. A tissue biopsy stained with Congo red dye remains the gold standard. Under polarized light, amyloid deposits produce a distinctive apple-green glow. But the choice of biopsy site matters. In one reported case, biopsies from bone marrow, a bone lesion, blood vessels, and fat pad all came back negative for amyloid, yet a later kidney biopsy revealed extensive AL amyloid deposits.16PubMed Central. AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report A negative biopsy from one site does not rule out the disease.
Once amyloid is confirmed, determining the exact protein type is critical because each type requires different treatment. Older methods used antibody-based staining panels that could identify the most common types but missed rarer ones. Mass spectrometry-based proteomics has become the most reliable method, capable of distinguishing all known amyloid types from a single tissue sample. In the large Mayo Clinic series, mass spectrometry identified 18 rare types that traditional panels would have missed entirely, including one type (ALECT2) that turned out to be more common than AA amyloidosis.7Mayo Clinic Proceedings. Typing of 16,175 Amyloidosis Specimens by Mass Spectrometry-Based Proteomics in a Clinical Laboratory
Diagnostic delays are a significant problem, particularly for cardiac ATTR amyloidosis. A review of the literature found that patients waited on average one to seven years between the onset of symptoms and a definitive diagnosis, and that a third to over half of patients received an incorrect diagnosis along the way.17PubMed Central. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review Common misdiagnoses include hypertensive heart disease, heart failure with preserved ejection fraction, and hypertrophic cardiomyopathy. These delays matter because treatment works best when started before organ damage is advanced.
How Amyloidosis Is Treated
Treatment strategy depends entirely on the type of amyloidosis, which is one of the main reasons accurate typing is so important. The therapies for AL amyloidosis look nothing like those for ATTR, and treating AA amyloidosis means treating whatever is causing the chronic inflammation in the first place.
AL Amyloidosis
The goal in AL amyloidosis is to eliminate or deeply suppress the plasma cell clone producing the toxic light chains. This is where the cancer-treatment overlap is most visible. The backbone of therapy includes drugs borrowed from the myeloma world: proteasome inhibitors like bortezomib, and anti-CD38 monoclonal antibodies like daratumumab. These drugs are highly effective at killing plasma cells and can produce deep responses in the majority of patients.18PubMed Central. Autologous stem cell transplantation in AL amyloidosis: Muddy waters
For patients healthy enough to tolerate it, high-dose melphalan chemotherapy followed by autologous stem cell transplant remains a standard-of-care approach offering long-term disease control.19Clinical Lymphoma, Myeloma and Leukemia. Systemic light chain (AL) amyloidosis is a multisystem disorder characterized by extracellular deposition of misfolded insoluble amyloid fibrils resulting in progressive organ dysfunction Patient selection is key, though. Because amyloid deposits have already weakened organs, the eligibility criteria for transplant in AL amyloidosis are more restrictive than in myeloma, and the drug doses used tend to be lower.4Hemato. Differences and Similarities in Treatment Paradigms and Goals between AL Amyloidosis and Multiple Myeloma Supportive care, including careful management of heart failure symptoms, fluid balance, and nutrition, is essential alongside disease-directed therapy to maximize both quality of life and the patient’s ability to tolerate treatment.20PubMed Central. Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
ATTR Amyloidosis
Since ATTR amyloidosis involves a normal (or mutated) transthyretin protein destabilizing and forming fibrils, the treatment logic is completely different from AL. No chemotherapy is used. Instead, the main approaches are:
- TTR stabilizers: Tafamidis works by binding to the transthyretin tetramer and preventing it from falling apart into the monomers that go on to form amyloid fibrils. It is approved for ATTR cardiomyopathy and has been shown to slow disease progression.21European Heart Journal. Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients
- Gene silencers: Patisiran, an RNA interference drug, stops the liver from making transthyretin altogether. It was approved in 2018 for hereditary ATTR polyneuropathy and has shown benefits even in patients who previously took tafamidis.22PubMed Central. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin‐mediated amyloidosis with polyneuropathy
- Antibody-based removal: Researchers are investigating monoclonal antibodies that target amyloid deposits already laid down in the heart, aiming to stimulate immune cells to clear the fibrils. This approach could complement stabilizers and silencers, which prevent new deposits but do not directly remove existing ones.23PubMed Central. Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
Gene Editing on the Horizon
Perhaps the most striking development in amyloidosis treatment is the arrival of CRISPR-based gene editing for ATTR. The idea is elegant: if the liver is the main factory producing troublesome transthyretin, you can use gene editing to permanently knock out the transthyretin gene in liver cells. An early clinical trial of NTLA-2001, a CRISPR-Cas9 therapy delivered via lipid nanoparticles, showed meaningful reductions in blood transthyretin levels in patients with ATTR amyloidosis.24PubMed. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
A similar gene-editing therapy called ART001 has shown equally promising early results. In a small trial of ten patients, those receiving higher doses achieved transthyretin reductions averaging 84–92% at 72 weeks after a single injection. No serious adverse events were reported.25PubMed Central. Clinical safety and tolerability of in vivo gene editing drug ART001 for ATTR amyloidosis If these results hold up in larger trials, a one-time treatment that permanently solves the protein-production problem would be transformative for ATTR patients who currently require ongoing infusions or daily pills.
Gene editing would not apply to AL amyloidosis, since the problem there is an abnormal bone marrow clone rather than a single gene in the liver. But the broader principle of targeting the source of amyloid at its genetic root reflects how quickly the treatment landscape is evolving. Two decades ago, many amyloidosis patients had few options; now, physicians can choose among stabilizers, gene silencers, monoclonal antibodies, chemotherapy, stem cell transplant, and potentially gene editing depending on the type and severity of disease.
How the Name Itself Causes Confusion
The word “amyloid” literally means “starch-like.” Rudolph Virchow coined it in 1854 after observing that certain abnormal tissue deposits stained blue with iodine, the same reaction used to detect starch. Virchow assumed the deposits were made of carbohydrate.26PubMed. Review: history of the amyloid fibril They turned out to be protein. By the time that was sorted out, the name had stuck. The misnomer contributes to public confusion: it does not sound like cancer, but it also does not sound like anything most people have heard of, leaving patients without an intuitive framework for understanding the disease.
Adding to the naming confusion, “amyloid” shows up in an entirely different high-profile context: Alzheimer’s disease, where amyloid-beta plaques accumulate in the brain. The protein is different, the disease is different, and the clinical overlap is essentially zero, but patients sometimes worry that one condition leads to the other. It does not. The word “amyloid” describes a structural pattern that proteins can adopt, not a single disease or substance. Any protein capable of forming those rigid, stacked-sheet fibrils can be called amyloid, which is why there are dozens of distinct amyloidoses rather than one unified disease.
Localized vs. Systemic and When You Should Worry
One practical question patients face is whether a finding of localized amyloid means they are at risk for the systemic, life-threatening versions. The answer, for the most part, is reassuring. In localized amyloidosis, the amyloid deposits at the site of production, so only one organ is disrupted.27Reviews in Health Care. Overview of systemic and localized amyloidosis In systemic amyloidosis, the misfolded protein is produced in one place (usually bone marrow or liver) and travels through the bloodstream to damage distant organs. These are fundamentally different scenarios. Patients with localized amyloid deposits are generally managed with local therapies like surgical excision and monitored over time, but they do not typically progress to systemic disease.11PubMed Central. The Story of Localized Amyloidosis: Something Old and Something New – A Case Series
That said, any new diagnosis of amyloidosis warrants thorough workup to confirm whether deposits are truly limited to one site. The stakes of missing systemic involvement are high, particularly if the heart or kidneys are silently accumulating amyloid. Blood and urine tests for abnormal light chains, cardiac biomarkers, and imaging studies can help distinguish localized from systemic disease without requiring biopsies of every organ.